Latigo Biotherapeutics prices $345.6M IPO at $18 per share

Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.

The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.

Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The offering is expected to close on Aug. 10, 2026, subject to customary closing conditions.

Goldman Sachs & Co. LLC, Jefferies, Leerink Partners, and Guggenheim Securities are serving as joint book-running managers for the offering.

Latigo's lead product candidate, LTG-001, is an oral Nav1.8 inhibitor in development for the treatment of acute pain. The SEC declared the company's registration statement effective on Aug. 6, 2026.

You May Also Be Interested In

• EShallGo closes $1.75M registered direct offering at $1 per share
• Karman Line Acquisition closes $200M IPO on Nasdaq
• Edesa Biotech prices $25M public offering on Nasdaq